<b><i>Background:</i></b> Chronic cerebral ischemia (CCI) is a form of cerebrovascular disease manifested as a vascular cognitive impairment (VCI). The management of the patients with CCI is determined by a healthy lifestyle and early therapy aimed at correcting and preventing this disease. Divaza is a drug with endothelial protective and nootropic effects. We present the final efficacy and safety analysis of all-Russian, open-label, prospective, observational, multicenter study of Divaza and emphasize the role of demographic and socioeconomic factors in cognitive disorder (CD) progression. <b><i>Methods:</i></b> CCI patients (<i>n</i> = 2,583) with or without CD were enrolled. Patients received Divaza (2 tablets 3 times per day for 12 weeks). Montreal Cognitive Assessment (MoCA) testing was required. The change in the mean MoCA score post-treatment was used as the primary endpoint. As the secondary endpoints, the number of patients with a MoCA &#x3c;26 and ≤17 (dementia); the percentage of patients with a MoCA score improvement in different age groups; the dynamics of mean MoCA score in age groups; and the relationship between CD and sex or regional social/economic factors were assessed. <b><i>Results:</i></b> Divaza therapy led to a significant improvement: the mean MoCA score was up to 20% higher post-treatment (Wilcoxon test, <i>p</i> &#x3c; 0.0001 vs. baseline). The number of participants with MoCA ≥26 increased by 33.6%. The number of patients with dementia was 4.1 times less after therapy (<i>p</i> &#x3c; 0.00001 vs. baseline). Divaza improved cognitive functions of patients in each age group. Findings demonstrate that regional socioeconomic factors contribute to CD development and severity. The observed divergence between sexes was a result of a larger number of women enrolled. The study confirmed the safety of Divaza. <b><i>Conclusions:</i></b> In the study, we observed the efficacy of Divaza for the treatment of CD: a therapy contributed to an increase in the mean MoCA score and the positive dynamics in the number of patients with cognitive improvement.

Cognitive disorders were identified in 90.7% of patients (<26 MoCA scores). After treatment, the mean MoCA score increased from 19.58±5.13 to 23.99±4.21 (p<0.0001), the number of patients with normal cognitive functions rate (≥26 scores) increased from 9.3 to 41.3%, the number of patients with marked cognitive impairment decreased. The drug was well-tolerated by old and very old patients, adverse events were observed rarely (0.6% of cases). The majority of doctors (88.4%) noticed the effect of divaza as significant improvement or improvement, and 89.6% of patients valued the effect to be excellent or good. The use of divaza, the drug with endothelioprotective and nootropic effects, is pathogenetically justified and promising in patients with cognitive disorders of vascular etiology.

The authors present an analysis of current research and their own data on the link between endothelial dysfunction (ED) and the severity of depression in middle-aged patients with cerebral microangiopathy. Levels of peripheral inflammatory and endothelial dysfunction markers were measured using the enzymelinked immunosorbent assay (ELISA). The results of the comparative and correlation analyses showed a statistically significant correlation between the severity of depression and increased levels of inflammatory, as well as endothelial dysfunction Keywords: inflammatory marker, endothelial dysfunction maker, depression, cerebral microangiopathy, Divaza Materials and methods, results, discussionThe study included middle-aged (44-60 years old) outpatients of both sexes, with cerebral microangiopathy. The diagnosis was based on (1) the presence of a

Широкое применение статинов с целью профилактики сердечно-сосудистых осложнений обусловливает важность тщательного изучения их воздействия на организм. До сих пор отсутствует однозначное мнение относительно влияния статинов на когнитивные функции (КФ).Цель исследования -оценить влияние 12-недельного курса статинов на параметры окислительного стресса и КФ у больных с церебральным атеросклерозом (ЦА) и умеренными когнитивными нарушениями.

No abstract